November 2026 Biotech Catalysts: Five PDUFAs Ranked

November 2026 is the second-densest PDUFA month of the fall. Three companies with market caps under $17 billion face FDA decisions in a 10-day window: SVRA on November 22, BBIO and GSK on November 27, and COGT on November 30. Each targets a different disease. Each has different binary risk-reward.

October resolved I-DXd, bepirovirsen, and INO-3107. The Q4 FDA calendar covers the full quarter. This piece ranks the November catalysts by tradeable risk-reward, with live market caps pulled from Polygon on August 7. Each links to a dedicated primer for the deep dive. One catalyst was already approved. It is flagged as a ghost.

Catalyst 1: SVRA MOLBREEVI (Nov 22): The Cleanest Data in the Slate

Savara (SVRA) at $5.83, $1.19 billion market cap. Zero revenue. One drug. One PDUFA.

MOLBREEVI (molgramostim) is an inhaled recombinant GM-CSF for autoimmune pulmonary alveolar proteinosis (aPAP), an ultra-rare lung disease with 2,000 to 9,000 diagnosed patients in the United States and zero FDA-approved therapies. The BLA rests on the Phase 3 IMPALA-2 trial (NCT04544293), a randomized, double-blind, placebo-controlled study of 164 patients. The primary endpoint: change in DLCO at Week 24. The result: a 6.00 percentage point improvement vs placebo (p=0.0007), published in NEJM. The improvement persisted at Week 48: 6.90 percentage points (p=0.0008).

The PDUFA date moved from August 22 to November 22 because the FDA determined that Savara’s responses to information requests constituted a major amendment. This is not a clinical hold or a CRL. Major amendments to a pending BLA routinely extend the review clock when the agency needs time to evaluate new data. The fact that the FDA asked questions and Savara answered with enough substance to trigger an extension means the application is under active review.

The SVRA MOLBREEVI primer covers the regulatory risks in depth. The bullish case is straightforward: clean Phase 3 data, NEJM peer review, Priority Review, zero approved therapies, and a disease where DLCO is the right endpoint. The bear case is that Savara has no commercial infrastructure and aPAP is small, with peak sales estimates of $300 to $500 million. At $1.19 billion, the market is pricing in approval plus a commercial launch. The binary is real.

Catalyst 2: BBIO BBP-418 (Nov 27): The First Drug That Reverses a Muscular Dystrophy

BridgeBio (BBIO) at $84.48, $16.55 billion market cap. BBIO has multiple approved drugs and multiple pipeline programs. BBP-418 is the next one.

BBP-418, branded Attruby, is an oral glycosylation substrate therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a monogenic autosomal recessive disease caused by FKRP mutations. Approximately 7,000 individuals live with it in the US and Europe. The disease progresses to loss of ambulation in 25% of adults, with cardiomyopathy in 30%. There are zero approved therapies.

The NDA is supported by the Phase 3 FORTIFY trial (NCT05775848), with results presented at the 2026 MDA Clinical and Scientific Conference. The primary endpoint, glycosylated αDG, increased 1.8x vs placebo at 3 months (p<0.0001) and was sustained at 12 months. Serum CK, a marker of muscle damage, dropped 82% (p<0.0001). On ambulatory function, the 100-meter timed test showed a velocity increase of 0.27 m/s vs placebo (p<0.0001). Pulmonary function (FVC) improved ~5% predicted vs placebo (p=0.0071).

This is not a halt in progression. This is improvement against a disease that only gets worse. The BBIO BBP-418 primer covers the trial in full. The FDA granted Priority Review and the drug has Rare Pediatric Disease Designation, which means approval triggers a Priority Review Voucher, worth $100 million on the open market.

At $16.55 billion, BBIO is the highest-valued company on the November slate. The market is already pricing in BBP-418 approval and launch success. The binary risk is lower than SVRA because BBIO has revenue from multiple approved drugs. A CRL would hurt but is not an existential event. A clean approval reinforces the BridgeBio multi-product thesis.

Catalyst 3: COGT Bezuclastinib GIST (Nov 30): The 50% Risk Reduction

Cogent Biosciences (COGT) at $42.39, $7.24 billion market cap. This is the higher-stakes COGT PDUFA. A second COGT PDUFA, for systemic mastocytosis, follows on December 30.

Correction: The upstream brief mislabeled this catalyst as “systemic mastocytosis.” The November 30 PDUFA is for bezuclastinib in combination with sunitinib in gastrointestinal stromal tumors (GIST). The systemic mastocytosis PDUFA is December 30.

Bezuclastinib is a KIT D816V inhibitor. The PEAK Phase 3 trial randomized patients with advanced GIST to bezuclastinib plus sunitinib vs sunitinib monotherapy. Results, presented at ASCO 2026: median PFS 16.5 months vs 9.2 months (HR=0.50, 95% CI: 0.39 to 0.65, p<0.0001). This is the first treatment ever to demonstrate a statistically significant advantage against an active comparator in second-line GIST. PFS2 was not reached vs 21 months (HR=0.57, 95% CI: 0.41 to 0.78). The FDA granted Breakthrough Therapy Designation, Priority Review, and Real-Time Oncology Review.

The data is clean. The HR of 0.50 is a 50% reduction in the risk of progression or death. The safety profile is manageable: Grade 3+ AEs included thrombocytopenia (27.4%), neutropenia (15.2%), anemia (9.3%), and diarrhea (7.8%). The COGT bezuclastinib GIST primer covers the regulatory path.

At $7.24 billion, COGT is priced for both approvals. A CRL on GIST would compress the stock meaningfully because investors are modeling dual approval of GIST in November and systemic mastocytosis in December. If GIST is approved, the stock runs into the December 30 SM PDUFA. The two-catalyst setup within 30 days creates an unusual binary window.

Catalyst 4: GSK Neladalkib (Nov 27): Mega-Cap Reality Check

GSK (GSK) at $52.96, $106 billion market cap. Neladalkib is an ALK-selective tyrosine kinase inhibitor for TKI-pretreated advanced ALK-positive non-small cell lung cancer, acquired via the Nuvalent deal that closed in late July 2026. The NDA was granted Priority Review with a November 27 PDUFA.

The drug is designed to stay active in tumors that developed resistance to first-, second-, and third-generation ALK inhibitors, including the G1202R mutation. The neladalkib primer covers the clinical data. The Jideytro approval already validated the Nuvalent platform, making neladalkib the second Nuvalent drug to reach the FDA.

At $106 billion market cap, neladalkib peak sales of $1 to $2 billion represent 1 to 2% of GSK revenue. The stock will not move on this approval. The thesis for a GSK position is the broader pipeline across bepirovirsen in HBV, Jideytro in ROS1, and the ViiV HIV franchise, not a single ALK inhibitor PDUFA. The catalyst is real but the trade is not.

Ghost: MRK KEYTRUDA + Trodelvy TNBC: Already Approved

The upstream brief listed MRK KEYTRUDA plus Trodelvy (sacituzumab govitecan) in 1L PD-L1+ TNBC as a November catalyst. The FDA approved this combination on June 24, 2026; six weeks before the brief was written. KEYNOTE-D19/ASCENT-04 showed median PFS of 11.2 months vs 7.8 months with KEYTRUDA plus chemotherapy (HR=0.65, 95% CI: 0.51 to 0.84, p=0.0009). At MRK’s $318 billion market cap, this was never a stock-mover. The catalyst is fully consumed. Rank it last. It is in the rear-view mirror.

Risks Across the Slate

All four live catalysts carry FDA risk, but the risk profiles differ. SVRA has the cleanest data in the smallest indication with the smallest company and zero financial buffer. BBIO delivered improvement vs placebo in a progressive disease at the highest market cap. COGT has the best hazard ratio (0.50) but faces a second catalyst 30 days later that doubles the binary risk. GSK has the lowest risk but zero tradeable reward at mega-cap scale.

The September slate taught us that PDUFA dates can shift and approvals can arrive early. The lesson applies to November: do not run concentrated positions into binary events that can move three months to the right or resolve six weeks early.

Verdict: Ranked by Tradeable Risk-Reward

1. SVRA MOLBREEVI (SVRA): Highest risk, highest reward. $1.19 billion market cap, zero revenue, one drug, clean Phase 3 data in an indication with no approved therapies. The 6-point DLCO delta is clinically meaningful and peer-reviewed in NEJM. The PDUFA extension is administrative, not clinical. Position size at 1 to 2% of a biotech portfolio. This is the only November catalyst where the stock doubles on approval or halves on a CRL.

2. COGT Bezuclastinib GIST (COGT): The 50% risk reduction is the largest statistical result on the November slate, but the dual-catalyst setup (SM on December 30) means investors are pricing two approvals, not one. Buy COGT for the GIST PDUFA but understand the position carries two binary events. If GIST is approved and the stock runs, trim into strength ahead of the December 30 SM decision.

3. BBIO BBP-418 (BBIO): The data shows improvement against a progressive disease with all endpoints met, but at the highest entry price ($16.55 billion). The risk-reward is compressed because the market is already pricing approval. Hold BBIO for the multi-product thesis, not for this single PDUFA.

4. GSK Neladalkib (GSK): Approval is likely. Stock impact is zero. At $106 billion, a $1 to $2 billion peak sales drug is a rounding error. Hold GSK for the pipeline, not for this PDUFA.

5. MRK KEYTRUDA + Trodelvy: Ghost. Approved June 24, 2026. Catalyst consumed. This one is in the rear-view mirror.

Looking ahead to December: COGT bezuclastinib systemic mastocytosis (Dec 30), VNDA imsidolimab GPP (Dec 12), and the tirabrutinib PCNSL decision. The catalyst calendar closes the year strong.